Physician profile
Daniel A Ebroon
NPI 1023050655
$25,687.24
in general payments reported to CMS, 2019-2025
21 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $73.42 · 2021: $9,946 · 2022: $581 · 2023: $1,361 · 2024: $1,064 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,223.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $20,752.25 | 2019-2022 | |
| Abbvie INC. | $875.22 | 2023-2025 | Vuity, Alphagan P, Lumigan |
| Amgen INC. | $540.16 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $539.58 | 2022-2025 | Envista Mx60 Iol, Miebo, Envista Aspire Iol |
| Tarsus Pharmaceuticals, INC. | $535.12 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $395.55 | 2021-2025 | Cequa |
| Oyster Point Pharma, INC. | $355.75 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Glaukos Corporation | $283.00 | 2023-2025 | Idosetr |
| Novartis Pharmaceuticals Corporation | $256.72 | 2019-2023 | |
| Horizon Therapeutics Plc | $224.76 | 2022-2023 | Tepezza |
| Alcon Vision LLC | $220.42 | 2025 | Clareon Panoptix Pro, Hydrus Microstent, Tryptyr |
| Dompe US, INC. | $159.91 | 2023-2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $116.33 | 2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $110.08 | 2023 | Izervay |
| Harrow Eye, LLC | $109.49 | 2024-2025 | Vevye |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $91.53 | 2019-2021 | |
| Biotissue Holdings INC. | $40.11 | 2023-2024 | |
| Shire North American Group INC | $23.55 | 2019 | |
| Akorn, INC. | $20.73 | 2019 | |
| Galderma Laboratories, L.P. | $18.53 | 2021 | |
| Thea Pharma INC. | $18.45 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ebroon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.